ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2024-2032

The market in China is growing rapidly due to the country’s aging population and increasing healthcare access. As the prevalence of Alzheimer’s disease rises, there is a growing demand for both therapeutics and diagnostic solutions. The adoption of advanced diagnostic technologies, such as brain imaging and cerebrospinal fluid (CSF) tests, is on the rise, improving early detection rates. The government’s focus on expanding healthcare infrastructure and increasing awareness about neurodegenerative diseases is further driving market growth.

Japan’s Alzheimer’s disease therapeutics & diagnostics market is one of the most advanced in the Asia-Pacific, largely due to the country’s aging population and strong healthcare system. The demand for effective therapeutic options, such as cholinesterase inhibitors and NMDA receptor antagonists, is high as more people are diagnosed with Alzheimer’s disease. Japan is also at the forefront of adopting cutting-edge diagnostic technologies, with significant advancements in brain imaging and CSF testing methods. Government initiatives, alongside private sector investments, continue to push the market forward, focusing on early diagnosis and improved treatment options for patients.

In India, the market is witnessing steady growth due to the increasing awareness of neurodegenerative diseases and a rapidly aging population. While the country’s healthcare infrastructure is still evolving, the demand for Alzheimer’s diagnostics and therapeutics is rising as more people seek early detection and better treatment options. Diagnostic technologies, such as brain imaging and CSF tests, are gradually becoming more accessible, especially in urban areas. The market is expected to expand further as healthcare reforms and government initiatives focus on the elderly population’s needs, fostering more awareness and improving access to treatments.

Likewise, South Korea’s Alzheimer’s disease therapeutics & diagnostics market is growing due to the country’s aging population and the rising incidence of Alzheimer’s among older adults. The market is characterized by a high level of healthcare sophistication, with advanced diagnostic methods, including brain imaging and CSF tests, being widely adopted for early detection. South Korea’s strong healthcare infrastructure and government focus on aging-related diseases contribute to the market’s growth. Additionally, the country is seeing an increase in the availability of therapeutic options, including cholinesterase inhibitors and NMDA receptor antagonists, as part of the broader effort to combat neurodegenerative diseases.

The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further differentiated into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics). 

NMDA receptor antagonists are a significant class of therapeutics in the Asia-Pacific market, used primarily to manage moderate to severe stages of Alzheimer’s disease. Further, these drugs work by blocking the N-methyl-D-aspartate (NMDA) receptors in the brain, which are involved in the regulation of glutamate, a neurotransmitter. By modulating glutamate activity, NMDA receptor antagonists help reduce excitotoxicity, which is thought to contribute to cognitive decline in Alzheimer’s patients. These medications, such as memantine, have shown efficacy in improving memory and cognitive functions, thus enhancing the quality of life for patients. Hence, the rising demand, awareness, and better healthcare access are driving the market for NMDA receptor antagonists in Alzheimer’s therapy.

Some of the leading players in the Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market include Eisai Co Ltd, Allergan PLC (acquired by AbbVie), Biogen Inc, Cognoptix Inc, etc.

Eisai Co Ltd, headquartered in Tokyo, Japan, is a global R&D-based pharmaceutical company focused on prescription medicines, with operations in R&D, manufacturing, distribution, and marketing. It has 15 drug discovery, R&D, and clinical research sites. Key therapeutic areas include neurology and oncology, with products like HALAVEN, Lenvima, and FYCOMPA. Additionally, the oncology pipeline features drug candidates such as MORAb-003 for ovarian cancer, MORAb-004 for melanoma, and E7090 for solid tumors.